Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

2.

Limited improvement of incorporating primary circulating prostate cells with the CAPRA score to predict biochemical failure-free outcome of radical prostatectomy for prostate cancer.

Murray NP, Aedo S, Fuentealba C, Jacob O, Reyes E, Novoa C, Orellana S, Orellana N.

Urol Oncol. 2016 Oct;34(10):430.e17-25. doi: 10.1016/j.urolonc.2016.05.020. Epub 2016 Jul 2.

PMID:
27381896
4.

Prediction model for early biochemical recurrence after radical prostatectomy based on the Cancer of the Prostate Risk Assessment score and the presence of secondary circulating prostate cells.

Murray NP, Aedo S, Reyes E, Orellana N, Fuentealba C, Jacob O.

BJU Int. 2016 Oct;118(4):556-62. doi: 10.1111/bju.13367. Epub 2015 Nov 25.

5.
6.
7.

Outcome of radical prostatectomy in primary circulating prostate cell negative prostate cancer.

Murray NP, Aedo S, Reyes E, Fuentealba C, Jacob O.

Ecancermedicalscience. 2016 Sep 1;10:671. doi: 10.3332/ecancer.2016.671. eCollection 2016.

8.

How localized is pathologically localized prostate cancer? The use of secondary circulating prostate cells as a marker of minimal residual disease and their association with patient outcome.

Murray NP, Aedo S, Fuentealba C, Reyes E, Jacob O.

Turk J Urol. 2017 Dec;43(4):456-461. doi: 10.5152/tud.2017.60251. Epub 2017 Dec 1.

9.

Elimination of primary circulating prostate cells after radical prostatectomy for prostate cancer decreases the risk of future biochemical failure.

Murray NP, Reyes E, Orellana N, Fuentealba C, Dueñas R.

Arch Esp Urol. 2014 Oct;67(8):684-91. English, Spanish.

PMID:
25306986
10.
11.

Validation of the Prostate Cancer Risk Index (PRIX): a simple scoring system to predict risk of biochemical relapse after radical prostatectomy for prostate cancer.

Yoshida T, Nakayama M, Matsuzaki K, Kobayashi Y, Takeda K, Arai Y, Kakimoto K, Nishimura K.

Jpn J Clin Oncol. 2011 Nov;41(11):1271-6. doi: 10.1093/jjco/hyr139. Epub 2011 Oct 4.

PMID:
21971422
12.
13.

Secondary circulating prostate cells predict biochemical failure in prostate cancer patients after radical prostatectomy and without evidence of disease.

Murray NP, Reyes E, Orellana N, Fuentealba C, Bádinez L, Olivares R, Porcell J, Dueñas R.

ScientificWorldJournal. 2013 Mar 31;2013:762064. doi: 10.1155/2013/762064. Print 2013.

14.

The presence of secondary circulating prostate tumour cells determines the risk of biochemical relapse for patients with low- and intermediate-risk prostate cancer who are treated only with external radiotherapy.

Murray NP, Aedo S, Fuentealba C, Reyes E, Minzer S, Salazar A.

Ecancermedicalscience. 2018 Jun 20;12:844. doi: 10.3332/ecancer.2018.844. eCollection 2018. Review.

15.
17.

A comparison of 3 on-line nomograms with the detection of primary circulating prostate cells to predict prostate cancer at initial biopsy.

Murray NP, Fuentealba C, Reyes E, Jacob O.

Actas Urol Esp. 2017 May;41(4):234-241. doi: 10.1016/j.acuro.2016.10.007. Epub 2017 Jan 17. English, Spanish.

PMID:
28108045
18.
19.

PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.

Roberts SG, Blute ML, Bergstralh EJ, Slezak JM, Zincke H.

Mayo Clin Proc. 2001 Jun;76(6):576-81.

PMID:
11393495
20.

Primary circulating prostate cells are not detected in men with low grade small volume prostate cancer.

Murray NP, Reyes E, Fuentealba C, Orellana N, Jacob O.

J Oncol. 2014;2014:612674. doi: 10.1155/2014/612674. Epub 2014 Aug 19.

Supplemental Content

Support Center